Point View Wealth Management Inc. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 90,817 shares of the biopharmaceutical company’s stock after buying an additional 4,507 shares during the period. Pfizer accounts for approximately 1.7% of Point View Wealth Management Inc.’s holdings, making the stock its 2nd biggest holding. Point View Wealth Management Inc.’s holdings in Pfizer were worth $3,934,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Weybosset Research & Management LLC increased its stake in Pfizer by 2.0% during the 2nd quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock worth $557,000 after purchasing an additional 250 shares in the last quarter. Congress Asset Management Co. MA increased its stake in Pfizer by 2.0% during the 4th quarter. Congress Asset Management Co. MA now owns 13,235 shares of the biopharmaceutical company’s stock worth $578,000 after purchasing an additional 254 shares in the last quarter. D.B. Root & Company LLC increased its stake in Pfizer by 0.7% during the 4th quarter. D.B. Root & Company LLC now owns 36,078 shares of the biopharmaceutical company’s stock worth $1,575,000 after purchasing an additional 255 shares in the last quarter. Cottage Street Advisors LLC increased its stake in Pfizer by 4.0% during the 4th quarter. Cottage Street Advisors LLC now owns 6,677 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 255 shares in the last quarter. Finally, Financial Gravity Wealth Inc. increased its stake in Pfizer by 33.2% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 257 shares in the last quarter. Institutional investors and hedge funds own 71.81% of the company’s stock.

In other news, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the sale, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Frank A. Damelio sold 153,184 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the completion of the sale, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

A number of analysts recently issued reports on the company. Bank of America cut Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. set a $46.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Monday, July 29th. UBS Group reissued a “neutral” rating and set a $43.00 target price on shares of Pfizer in a research note on Monday, August 5th. Morgan Stanley cut Pfizer from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $48.00 to $40.00 in a research note on Tuesday, July 30th. Finally, Goldman Sachs Group reissued a “buy” rating and set a $49.00 target price on shares of Pfizer in a research note on Monday, June 17th. Fourteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Pfizer currently has an average rating of “Hold” and a consensus target price of $46.56.

Shares of NYSE PFE traded up $0.19 during trading hours on Tuesday, hitting $35.58. The company had a trading volume of 1,013,823 shares, compared to its average volume of 30,291,382. The stock has a market capitalization of $202.10 billion, a PE ratio of 11.88, a P/E/G ratio of 2.90 and a beta of 0.63. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27. Pfizer Inc. has a 1-year low of $35.86 and a 1-year high of $46.47. The firm’s 50 day moving average price is $41.55.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 27.57% and a net margin of 23.58%. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 EPS. Equities research analysts expect that Pfizer Inc. will post 2.8 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be issued a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 4.05%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s payout ratio is presently 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Insider Trading – What You Need to Know

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.